Shanghai Pharmaceuticals (02607.HK): Shang Yao Guofeng's Rosuvastatin capsules have been approved for production.

Intelligence Finance APP News, Shanghai Pharmaceuticals (02607.HK) announced that recently, the company's subsidiary Shanghai Pharmaceuticals Group Qingdao Guofeng Pharmaceutical Co., Ltd. (referred to as "Shanghai Guofeng") received the "Drug Registration Certificate" (Certificate No.: 2026S01898, 2026S01899) issued by the National Medical Products Administration for its rosuvastatin capsules, and the drug has been approved for production.